vs
Side-by-side financial comparison of AdvanSix Inc. (ASIX) and IDEAYA Biosciences, Inc. (IDYA). Click either name above to swap in a different company.
AdvanSix Inc. is the larger business by last-quarter revenue ($359.9M vs $207.8M, roughly 1.7× IDEAYA Biosciences, Inc.). IDEAYA Biosciences, Inc. runs the higher net margin — 57.4% vs -0.8%, a 58.2% gap on every dollar of revenue. IDEAYA Biosciences, Inc. produced more free cash flow last quarter ($142.2M vs $36.1M).
AdvanSix Inc. is an American chemical company that produces nylon 6 and related chemicals such as caprolactam and ammonium sulfate fertilizers. It operated as Honeywell's Resins and Chemicals division until 2016, when it was spun off as a separate company. The unit accounted for 3 percent of Honeywell's sales at the time. For 2019, revenue is estimated at $1.4 billion. The company traces its lineage to the H. W. Jayne Company, established 1884 in Frankford, Pennsylvania.
IDEAYA Biosciences, Inc. is a clinical-stage biotechnology company focused on oncology, developing targeted therapies and synthetic lethality treatments for patients with genetically defined cancers. It advances a pipeline of candidates across multiple tumor types, partnering with industry stakeholders to accelerate global access to innovative cancer care solutions.
ASIX vs IDYA — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $359.9M | $207.8M |
| Net Profit | $-2.8M | $119.2M |
| Gross Margin | 7.6% | — |
| Operating Margin | -0.7% | 52.2% |
| Net Margin | -0.8% | 57.4% |
| Revenue YoY | 9.4% | — |
| Net Profit YoY | -892.9% | 330.1% |
| EPS (diluted) | $-0.11 | $1.33 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $359.9M | — | ||
| Q3 25 | $374.5M | $207.8M | ||
| Q2 25 | $410.0M | — | ||
| Q1 25 | $377.8M | — | ||
| Q4 24 | $329.1M | — | ||
| Q3 24 | $398.2M | $0 | ||
| Q2 24 | $453.5M | $0 | ||
| Q1 24 | $336.8M | $0 |
| Q4 25 | $-2.8M | — | ||
| Q3 25 | $-2.6M | $119.2M | ||
| Q2 25 | $31.4M | — | ||
| Q1 25 | $23.3M | — | ||
| Q4 24 | $352.0K | — | ||
| Q3 24 | $22.3M | $-51.8M | ||
| Q2 24 | $38.9M | $-52.8M | ||
| Q1 24 | $-17.4M | $-39.6M |
| Q4 25 | 7.6% | — | ||
| Q3 25 | 6.8% | — | ||
| Q2 25 | 14.3% | — | ||
| Q1 25 | 14.2% | — | ||
| Q4 24 | 3.4% | — | ||
| Q3 24 | 14.4% | — | ||
| Q2 24 | 17.9% | — | ||
| Q1 24 | 0.9% | — |
| Q4 25 | -0.7% | — | ||
| Q3 25 | -0.9% | 52.2% | ||
| Q2 25 | 7.7% | — | ||
| Q1 25 | 7.7% | — | ||
| Q4 24 | -3.9% | — | ||
| Q3 24 | 7.5% | — | ||
| Q2 24 | 11.5% | — | ||
| Q1 24 | -7.0% | — |
| Q4 25 | -0.8% | — | ||
| Q3 25 | -0.7% | 57.4% | ||
| Q2 25 | 7.7% | — | ||
| Q1 25 | 6.2% | — | ||
| Q4 24 | 0.1% | — | ||
| Q3 24 | 5.6% | — | ||
| Q2 24 | 8.6% | — | ||
| Q1 24 | -5.2% | — |
| Q4 25 | $-0.11 | — | ||
| Q3 25 | $-0.10 | $1.33 | ||
| Q2 25 | $1.15 | — | ||
| Q1 25 | $0.86 | — | ||
| Q4 24 | $0.02 | — | ||
| Q3 24 | $0.82 | $-0.60 | ||
| Q2 24 | $1.43 | $-0.68 | ||
| Q1 24 | $-0.65 | $-0.53 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $19.8M | $786.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $815.2M | $1.1B |
| Total Assets | $1.7B | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $19.8M | — | ||
| Q3 25 | $23.7M | $786.9M | ||
| Q2 25 | $18.4M | — | ||
| Q1 25 | $8.3M | — | ||
| Q4 24 | $19.6M | — | ||
| Q3 24 | $17.3M | $920.0M | ||
| Q2 24 | $12.1M | $701.7M | ||
| Q1 24 | $20.6M | $698.8M |
| Q4 25 | $815.2M | — | ||
| Q3 25 | $818.2M | $1.1B | ||
| Q2 25 | $823.7M | — | ||
| Q1 25 | $794.4M | — | ||
| Q4 24 | $774.6M | — | ||
| Q3 24 | $766.4M | $1.2B | ||
| Q2 24 | $746.6M | $931.7M | ||
| Q1 24 | $713.2M | $935.3M |
| Q4 25 | $1.7B | — | ||
| Q3 25 | $1.7B | $1.2B | ||
| Q2 25 | $1.6B | — | ||
| Q1 25 | $1.6B | — | ||
| Q4 24 | $1.6B | — | ||
| Q3 24 | $1.5B | $1.2B | ||
| Q2 24 | $1.5B | $973.7M | ||
| Q1 24 | $1.5B | $961.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $63.7M | $142.2M |
| Free Cash FlowOCF − Capex | $36.1M | $142.2M |
| FCF MarginFCF / Revenue | 10.0% | 68.4% |
| Capex IntensityCapex / Revenue | 7.7% | 0.0% |
| Cash ConversionOCF / Net Profit | — | 1.19× |
| TTM Free Cash FlowTrailing 4 quarters | $6.4M | $13.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $63.7M | — | ||
| Q3 25 | $26.6M | $142.2M | ||
| Q2 25 | $21.1M | — | ||
| Q1 25 | $11.4M | — | ||
| Q4 24 | $64.2M | — | ||
| Q3 24 | $57.3M | $-49.2M | ||
| Q2 24 | $50.2M | $-32.9M | ||
| Q1 24 | $-36.2M | $-43.8M |
| Q4 25 | $36.1M | — | ||
| Q3 25 | $66.0K | $142.2M | ||
| Q2 25 | $-7.2M | — | ||
| Q1 25 | $-22.6M | — | ||
| Q4 24 | $29.8M | — | ||
| Q3 24 | $26.8M | $-49.7M | ||
| Q2 24 | $16.7M | $-33.9M | ||
| Q1 24 | $-71.6M | $-45.1M |
| Q4 25 | 10.0% | — | ||
| Q3 25 | 0.0% | 68.4% | ||
| Q2 25 | -1.7% | — | ||
| Q1 25 | -6.0% | — | ||
| Q4 24 | 9.1% | — | ||
| Q3 24 | 6.7% | — | ||
| Q2 24 | 3.7% | — | ||
| Q1 24 | -21.3% | — |
| Q4 25 | 7.7% | — | ||
| Q3 25 | 7.1% | 0.0% | ||
| Q2 25 | 6.9% | — | ||
| Q1 25 | 9.0% | — | ||
| Q4 24 | 10.4% | — | ||
| Q3 24 | 7.7% | — | ||
| Q2 24 | 7.4% | — | ||
| Q1 24 | 10.5% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 1.19× | ||
| Q2 25 | 0.67× | — | ||
| Q1 25 | 0.49× | — | ||
| Q4 24 | 182.29× | — | ||
| Q3 24 | 2.57× | — | ||
| Q2 24 | 1.29× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ASIX
| Plant Nutrients | $140.0M | 39% |
| Chemical Intermediates | $92.8M | 26% |
| Caprolactam | $64.4M | 18% |
| Nylon Resins | $62.8M | 17% |
IDYA
Segment breakdown not available.
